MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Home・Elenco Azioni・CEL-SCI Corp

CEL-SCI Corp

Chiusa

SettoreSettore sanitario

3.17 6.38

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.95

Massimo

3.18

Metriche Chiave
By Trading Economics
Entrata	631K -5.5M
EPS	-0.68
EBITDA	607K -4.4M

Dividendi
By Dow Jones
Utili prossimi	14 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-12M 29M
Apertura precedente	-3.21
Chiusura precedente	3.17

Notizie sul Sentiment di mercato

By Acuity

50%

148 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

N/A / 0.2494 Supporto e resistenza

CEL-SCI Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 mar 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Utili

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisizioni, Fusioni, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Utili

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Discorsi di Mercato

Utili

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Discorsi di Mercato

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisizioni, Fusioni, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Discorsi di Mercato

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Utili

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Utili

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Utili

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Utili

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Utili

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Utili

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Utili

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Utili

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Discorsi di Mercato

Utili

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Utili

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Utili

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Utili

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Utili

Nike CEO: Converse Remains Important to Portfolio

Confronto tra pari

Modifica del prezzo

CEL-SCI Corp Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 0 che hanno fornito valutazioni azionarie a CEL-SCI Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 0.2494Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bullish event.

There is one bearish event.

Sentiment

By Acuity

148 / 349 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Altri titoli del settore

MDT

Medtronic PLC

86.56

↑ +0.83%

Agilent Technologies Inc

113.95

↑ +1.74%

VEEV

Veeva Systems Inc

175.31

↑ +0.07%

HQY

HealthEquity Inc

83.18

↑ +1.87%

CSBR

Champions Oncology Inc

5.69

↑ +2.34%

CEL-SCI Corp

Panoramica

Variazione del prezzo dell'azione

Metriche Chiave

Dividendi

Statistiche di mercato

Notizie sul Sentiment di mercato

Punteggio Tecnico

CEL-SCI Corp Grafico

Notizie correlate

Confronto tra pari

CEL-SCI Corp Previsione

Consenso sulla valutazione

Punteggio Tecnico

Sentiment

Notizie finanziarie

Altri titoli del settore